London – Following clinical trials, a Covid-19 vaccine developed by the University of Oxford in collaboration with AstraZeneca has proven to be effective, the University has announced.
According to the University in its website, while the preliminary data suggests that the vaccine prevents 70% of infections, it could prevent up to 90% of infections, depending on how the vaccine is administered.
There were no hospitalisations or severe cases of the disease amongst those who received the vaccine, the report stated.
Crucially, the vaccine can be easily administered in existing healthcare systems, as it can be stored at fridge temperature (2-8 °C).
The full safety data and findings will need to be peer reviewed before a vaccine can be approved for use.
If approved, up to 3 billion doses could be manufactured in 2021.
The vaccine will be provided on a not-for-profit basis for the duration of the pandemic, and in perpetuity to low- and middle-income countries.
The UK government is supporting the development and fair distribution of a coronavirus vaccine through the COVAX facility.
This ensures we have the best chance of accessing a safe and effective vaccine for people in the UK as soon as one becomes available, as well as supporting access in poorer countries.
Find out more: https://www.ox.ac.uk/news/2020-11-23-oxford-university-breakthrough-global-covid-19-vaccine